Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK548470 vs Entecavir in Treatment-Naïve Chronic Hepatitis B
NCT01480284Phase 3Completed
- Sponsor
- GSK
- Start
- Nov 2011
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tenofovir disoproxil fumarate in Chronic Hepatitis B (CHB) (2 arms), sponsored by GSK. Primary endpoint: Mean Change From Baseline in Serum HBV DNA Level at 24 weeks. Started Nov 2011; status: completed.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT01480284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01480284.